. “By studying untapped psychedelics in a scientific setting, we believe we can unlock and standardize their healing power. This is a promising step forward in our mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible,” Moss said.Article content
“The benefits of these valuable plants are well-documented; we will be among the first to purposefully explore their pharmaceutical applications,” said company CEO Benjamin Lightburn.administered in clinical trials Another Vancouver-based company, Algernon Pharmaceuticals, is also studying DMT, a psychedelic compound that is part of the tryptamine family, alongside substances like psilocybin, ketamine and LSD, as a possible treatment option for stroke.